INTERPRETATION Continued cannabis use after onset of psychosis predicts adverse outcome , including higher relapse rates , longer hospital admissions , and more severe positive symptoms than for individuals who discontinue cannabis use and those who are non-users .
BACKGROUND Although the link between cannabis use and development of psychosis is well established , less is known about the effect of continued versus discontinued cannabis use after the onset of psychosis .
We aim ed to summarise available evidence focusing on the relationship between continued and discontinued cannabis use after onset of psychosis and its relapse .
Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction
BACKGROUND Recent advances in the neurobiology of cannabinoids have renewed interest in the association between cannabis and psychotic disorders . METHODS In a 3-day , double-blind , r and omized , placebo-controlled study , the behavioral , cognitive , motor , and endocrine effects of 0 mg , 2.5 mg , and 5 mg intravenous Delta-9-tetrahydrocannabinol ( Delta-9-THC ) were characterized in 13 stable , antipsychotic-treated schizophrenia patients . These data were compared with effects in healthy subjects reported elsewhere . RESULTS Delta-9-tetrahydrocannabinol transiently increased 1 ) learning and recall deficits ; 2 ) positive , negative , and general schizophrenia symptoms ; 3 ) perceptual alterations ; 4 ) akathisia , rigidity , and dyskinesia ; 5 ) deficits in vigilance ; and 6 ) plasma prolactin and cortisol .  Schizophrenia patients were more vulnerable to Delta-9-THC effects on recall relative to control subjects . There were no serious short- or long-term adverse events associated with study participation . CONCLUSIONS Delta-9-tetrahydrocannabinol is associated with transient exacerbation in core psychotic and cognitive deficits in schizophrenia . These data do not provide a reason to explain why schizophrenia patients use or misuse cannabis . Furthermore , Delta-9-THC might differentially affect schizophrenia patients relative to control subjects . Finally , the enhanced sensitivity to the cognitive effects of Delta-9-THC warrants further study into whether brain cannabinoid receptor dysfunction contributes to the pathophysiology of the cognitive deficits associated with schizophrenia
INTERPRETATION Continued cannabis use after onset of psychosis predicts adverse outcome , including higher relapse rates , longer hospital admissions , and more severe positive symptoms than for individuals who discontinue cannabis use and those who are non-users .
BACKGROUND Although the link between cannabis use and development of psychosis is well established , less is known about the effect of continued versus discontinued cannabis use after the onset of psychosis .
We aim ed to summarise available evidence focusing on the relationship between continued and discontinued cannabis use after onset of psychosis and its relapse .